Edition:
United States

Avadel Pharmaceuticals PLC (AVDL.OQ)

AVDL.OQ on NASDAQ Stock Exchange Global Market

8.95USD
3:14pm EST
Change (% chg)

$0.02 (+0.22%)
Prev Close
$8.93
Open
$8.92
Day's High
$9.06
Day's Low
$8.85
Volume
39,634
Avg. Vol
49,402
52-wk High
$12.30
52-wk Low
$7.53

Latest Key Developments (Source: Significant Developments)

Avadel Pharmaceuticals Plc says Avadel licensee and Serenity amended exclusivity agreement on Sept 1
Tuesday, 5 Sep 2017 05:45pm EDT 

Sept 5 (Reuters) - Avadel Pharmaceuticals Plc :Avadel Pharmaceuticals Plc says on September 1, 2017, Avadel licensee and Serenity amended exclusivity agreement.Avadel Pharma-under amendment $5 million deposited into escrow by Avadel licensee will continue to be held & will deposit additional $47 million - SEC filing.  Full Article

Avadel Pharmaceuticals Plc ‍enters into a license agreement with Serenity Pharmaceuticals Llc​
Tuesday, 5 Sep 2017 04:05pm EDT 

Sept 5 (Reuters) - Avadel Pharmaceuticals Plc :Avadel Pharmaceuticals Plc - ‍entered into a license agreement with Serenity Pharmaceuticals Llc​.Avadel Pharmaceuticals Plc - ‍deal includes $50 million upfront payment; funded by cash on hand​.Avadel - ‍terms of agreement also include $20 million due at earlier of full scale commercial launch or June 30, 2018, performance-based milestones​.  Full Article

Avadel Pharmac enters into negotiations with Serenity Pharma for Noctiva
Thursday, 17 Aug 2017 04:05pm EDT 

Aug 17 (Reuters) - Avadel Pharmaceuticals Plc :Avadel Pharmaceuticals enters into exclusive negotiations with Serenity Pharmaceuticals for Noctiva™.Avadel Pharmaceuticals Plc - ‍entered into an agreement for right to exclusively negotiate with Serenity Pharmaceuticals, Llc.Avadel Pharmaceuticals Plc - ‍agreement with serenity for sole rights to commercialize and further develop Noctiva in united states and canada​.Avadel Pharmaceuticals Plc - ‍exclusive negotiation period is expected to close on or before September 7, 2017​.Avadel Pharmaceuticals Plc - ‍if Avadel terminates negotiations without cause, Avadel must pay $10 million to Serenity​.Avadel Pharmaceuticals Plc - ‍if serenity terminates negotiations without cause, Serenity must pay $10 million to Avadel​.  Full Article

Avadel Pharmaceuticals reports Q2 GAAP earnings per share $0.68
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Avadel Pharmaceuticals PLC :Avadel Pharmaceuticals reports second quarter 2017 results.Q2 adjusted earnings per share $0.19.Q2 GAAP earnings per share $0.68.Q2 revenue $46.3 million versus I/B/E/S view $45.2 million.Q2 earnings per share view $0.04 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $165 million to $175 million.Avadel Pharmaceuticals PLC says FY diluted adjusted EPS is unchanged from previous guidance of $0.30 to $0.45..  Full Article

Avadel Pharmaceuticals Q1 GAAP earnings per share $0.59
Tuesday, 9 May 2017 07:30am EDT 

May 9 (Reuters) - Avadel Pharmaceuticals Plc : :Avadel Pharmaceuticals reports first quarter 2017 results.Q1 adjusted earnings per share $0.26.Q1 GAAP earnings per share $0.59.Q1 revenue $52.5 million versus I/B/E/S view $46.1 million.Raises FY 2017 adjusted earnings per share view to $0.30 to $0.45.Sees FY 2017 revenue $170 million to $185 million.Q1 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $0.03, revenue view $175.2 million -- Thomson Reuters I/B/E/S.Avadel Pharmaceuticals - included in GAAP net income in q1 2017 are $2.7 million in restructuring costs related to reduction of co's workforce in France.  Full Article

Avadel Pharmaceuticals says plans to reduce headcount in France by About 50 people
Thursday, 30 Mar 2017 04:03pm EDT 

Avadel Pharmaceuticals Plc : Avadel Pharmaceuticals announces planned reduction of french workforce . Avadel Pharmaceuticals Plc - announced a plan to reduce its headcount in France by approximately 50 peopl . Avadel Pharmaceuticals Plc - anticipates annual costs savings of about $3.5 to $4.0 million . Avadel Pharmaceuticals Plc - action does not affect allocation of resources to its rest-on Phase III clinical trial or any other important pipeline initiatives . Avadel Pharmaceuticals Plc - expects reduction to be substantially completed by end of July 2017 .Avadel Pharmaceuticals Plc- expects to incur related employee severance, benefits and other costs of approximately $2.5 to $4.0 million.  Full Article

Avadel Pharmaceuticals files for non-timely 10-K
Thursday, 16 Mar 2017 05:33pm EDT 

Avadel Pharmaceuticals Plc : Files for non-timely 10-K - SEC filing . Avadel Pharmaceuticals - expects to file annual report on form 10-K within the extension period of 15 calendar days as provided under rule 12B-25 . Avadel Pharmaceuticals - expects to report total revenues of about $150 million for 2016 versus total revenues of about $173 million for 2015 . Avadel Pharmaceuticals - expects to report net loss of about $41 million for 2016 versus net income of about $42 million for 2015 Source: (http://bit.ly/2mxzb5w) Further company coverage: [AVDL.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Avadel Pharmaceuticals reports Q4 EPS $0.11
Tuesday, 7 Mar 2017 06:30am EST 

Avadel Pharmaceuticals Plc - : Avadel Pharmaceuticals reports fourth quarter and full year 2016 results . Q4 adjusted earnings per share $0.00 . Q4 gaap earnings per share $0.11 . Q4 revenue $43.1 million versus i/b/e/s view $34.9 million . Q4 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S . Reaffirms fy 2017 adjusted earnings per share view $0.20 to $0.35 . Sees fy 2017 revenue $170 million to $200 million .Fy2017 earnings per share view $0.17, revenue view $171.9 million -- Thomson Reuters I/B/E/S.  Full Article

Flamel technologies announces shareholder approval of cross-border merger
Friday, 12 Aug 2016 07:30am EDT 

Flamel Technologies Sa : Avadel Pharmaceuticals limited will re-register as irish public limited co and will be known as Avadel Pharmaceuticals Plc . Flamel technologies announces shareholder approval of cross-border merger . Received shareholder approval to reincorporate its country of domicile to Ireland from France via a cross-border merger .Under terms of reincorporation, Flamel will merge with and into its wholly owned subsidiary, Avadel Pharmaceuticals Ltd.  Full Article

Flamel Technologies reports Q2 GAAP loss per share $0.48
Monday, 8 Aug 2016 06:05am EDT 

Flamel Technologies SA : Total revenue for Q2 2016 was $38.9 million, compared to $48.6 million during same period last year . Q2 adjusted loss per share $0.02 . Q2 GAAP loss per share $0.48 . Has lowered its 2016 research and development spending guidance to range or $30 to $40 million .2016 revenue guidance increased to $125 to $140 million.  Full Article